New treatment may offer lasting cure for hormone-related hypertension

Although aldosterone synthase inhibitors have previously been tested in larger studies of people with hypertension, these generally involved shorter treatment periods of 6–12 weeks, with outcomes measured during treatment. In contrast, the new Queen Mary-led study found that the benefits of 6–12 months of treatment persisted for up to two years after treatment had ended.

Mason Freeman, Professor of Medicine at Harvard Medical School and initiator of the original study while medical director at Cincor, said "This follow up study led by Dr. Brown has generated some extraordinary and unexpected findings. The sustained remission in the biochemical markers of the hyperaldosterone state, combined with much improved blood pressure levels, offers the very exciting possibility that many patients with primary aldosteronism may be able to be treated with a once a day pill, perhaps for a limited period of time, and obtain similar benefits to what we now achieve only after invasive diagnostic testing and major adrenal surgery."

Source:

Queen Mary University of London

Journal reference: